Compare AMPG & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMPG | MREO |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | United States | United Kingdom |
| Employees | 47 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.7M | 52.5M |
| IPO Year | N/A | 2017 |
| Metric | AMPG | MREO |
|---|---|---|
| Price | $4.99 | $0.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $7.00 | $1.50 |
| AVG Volume (30 Days) | ★ 2.9M | 1.8M |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | $102.41 | $5,184.20 |
| Revenue Next Year | $20.00 | $55.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.64 | $0.20 |
| 52 Week High | $5.60 | $2.94 |
| Indicator | AMPG | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 81.83 | 49.24 |
| Support Level | $2.73 | $0.21 |
| Resistance Level | N/A | $0.36 |
| Average True Range (ATR) | 0.50 | 0.03 |
| MACD | 0.31 | 0.01 |
| Stochastic Oscillator | 82.49 | 55.27 |
AmpliTech Group Inc designs, develops, engineers, and assembles micro-wave component-based amplifiers that meet individual customer specifications. It operates in two segments: the manufacturing and engineering segment. The products of the company consist of RF amplifiers & related subsystems, operating at multiple frequencies from 50kHz to 44GHz, including Low Noise Amplifiers, Medium Power Amplifiers, cryogenic amplifiers, and custom assemblies. The company also offers non-recurring engineering services on a project-by-project basis, for a predetermined fixed contractual amount, or on a time-plus-material basis. It also operates as a manufacturer, & distributor of cryogenic microwave amplifiers, RF designs, & applications for Wireless Networks & the future of Wireless Communication.
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).